文献速递糖尿病肥胖与代谢综合征

2型糖尿病患者胃旁路术后减重对肾脏和心血管结局的影响:心肾风险降低超过动脉粥样硬化获益

Renal and Cardiovascular Outcomes After Weight Loss From Gastric Bypass Surgery in Type 2 Diabetes: Cardiorenal Risk Reductions Exceed Atherosclerotic Benefits.
PubMed 文献 · Diabetes Care · 2020-03-09

一项全国性队列研究匹配5321例接受胃旁路术的2型糖尿病肥胖患者与5321例未手术者,随访超4.5年。胃旁路术后心力衰竭(HR 0.33)和心血管死亡(HR 0.36)风险大幅降低,严重肾脏病或eGFR减半复合风险为0.56,非致死性心血管风险降低较少(HR 0.82)。

要点

  • 胃旁路术后心衰风险HR 0.33,心血管死亡HR 0.36,肾脏复合终点HR 0.56。
  • 非致死性心血管风险降低较少,HR 0.82。
  • 各eGFR分层(包括eGFR<30 mL/min/1.73 m2)风险普遍降低。

核心结论

  • 数据提示胃旁路术对肥胖合并2型糖尿病患者的肾脏结局、心力衰竭和心血管死亡有稳健获益。
  • 显著减重对心肾轴(包括延缓进展至终末期肾病)产生重要获益,无论基线肾功能状态如何。

研究设计与样本

  • 全国性队列研究,链接国家糖尿病登记处和斯堪的纳维亚肥胖手术登记处与四个国家数据库。
  • 匹配5321例接受胃旁路术的2型糖尿病患者与5321例未手术者,年龄18-65岁,平均BMI>40 kg/m2,平均随访>4.5年。
  • 采用Cox回归模型评估术后结局风险。

主要发现

  • 术后最初几年,胃旁路术组肌酐和白蛋白尿小幅降低,估算肾小球滤过率(eGFR)稳定。
  • 心力衰竭风险HR 0.33(95% CI 0.24, 0.46),心血管死亡风险HR 0.36(95% CI 0.22, 0.58)。
  • 严重肾脏病或eGFR减半复合风险HR 0.56(95% CI 0.44, 0.71),非致死性心血管风险HR 0.82(95% CI 0.70, 0.97)。
  • 所有eGFR分层(包括eGFR<30 mL/min/1.73 m2)中,胃旁路术后关键结局风险普遍较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined detailed renal and cardiovascular (CV) outcomes after gastric bypass (GBP) surgery in people with obesity and type 2 diabetes mellitus (T2DM), across several renal function categories, in a nationwide cohort study. RESEARCH DESIGN AND METHODS: We linked data from the National Diabetes Register and the Scandinavian Obesity Surgery Register with four national databases holding information on socioeconomic variables, medications, hospitalizations, and causes of death and matched 5,321 individuals with T2DM who had undergone GBP with 5,321 who had not (age 18-65 years, mean BMI >40 kg/m2, mean follow-up >4.5 years). The risks of postoperative outcomes were assessed with Cox regression models. RESULTS: During the first years postsurgery, there were small reductions in creatinine and albuminuria and stable estimated glomerular filtration rate (eGFR) in the GBP group. The incidence rates of most outcomes relating to renal function, CV disease, and mortality were lower after GBP, being particularly marked for heart failure (hazard ratio [HR] 0.33 [95% CI 0.24, 0.46]) and CV mortality (HR 0.36 [(95% CI 0.22, 0.58]). The risk of a composite of severe renal disease or halved eGFR was 0.56 (95% CI 0.44, 0.71), whereas nonfatal CV risk was lowered less (HR 0.82 [95% CI 0.70, 0.97]) after GBP. Risks for key outcomes were generally lower after GBP in all eGFR strata, including in individuals with eGFR <30 mL/min/1.73 m2. CONCLUSIONS: Our data suggest robust benefits for renal outcomes, heart failure, and CV mortality after GBP in individuals with obesity and T2DM. These results suggest that marked weight loss yields important benefits, particularly on the cardiorenal axis (including slowing progression to end-stage renal disease), whatever the baseline renal function status.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Liakopoulos V, Franzén S, Svensson AM, et al. Renal and Cardiovascular Outcomes After Weight Loss From Gastric Bypass Surgery in Type 2 Diabetes: Cardiorenal Risk Reductions Exceed Atherosclerotic Benefits. Diabetes Care. 2020. PMID: 32152136. doi:10.2337/dc19-1703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。